Drug-Drug Interactions with Vesicular Monoamine Transporter 2 Inhibitors: Population Estimate of Patients With Tardive Dyskinesia at Risk in Real-World Clinical Practice
Sign Up to like & getrecommendations! Published in 2024 at "CNS Spectrums"
DOI: 10.1017/s1092852924001639
Abstract: Introduction Valbenazine and deutetrabenazine (vesicular monoamine transporter 2 inhibitors) are approved for tardive dyskinesia (TD) treatment in adults. To prevent potential drug-drug interactions (DDIs), valbenazine labeling recommends doses 40 mg/day when taking strong CYP3A4 or… read more here.
Keywords: risk; deutetrabenazine; drug; proportions patients ... See more keywords